Sander Dale A. 4
4 · Humacyte, Inc. · Filed Dec 12, 2023
Insider Transaction Report
Form 4
Humacyte, Inc.HUMA
Sander Dale A.
CFO and Chief Corp. Deve. Off.
Transactions
- Award
Stock Options (right to buy)
2023-12-08+301,000→ 301,000 totalExercise: $2.80Exp: 2033-12-08→ Common Stock (301,000 underlying) - Award
Stock Options (right to buy)
2023-12-11+525→ 2,100 totalExercise: $10.28From: 2023-12-11Exp: 2030-12-14→ Common Stock (525 underlying)
Footnotes (2)
- [F1]The first 25% of the option becomes exercisable on December 8, 2024, after which 1/48 of the option will become exercisable on the 8th of each month through December 8, 2027.
- [F2]On December 14, 2020, Humacyte granted options to purchase 2,625 shares of common stock, which vest as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application ("BLA") to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Humacyte previously reported three-fifths of the option grant on a Form 4 filed on August 27, 2021. On December 11, 2023 Humacyte submitted a BLA to the FDA. Accordingly, columns 5 and 7 of Table II report the number of securities equal to one-fifth of the 12/14/2020 option grant.